Leonteq Securities AG Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Leonteq Securities AG bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,342 shares of the biopharmaceutical company’s stock, valued at approximately $1,036,000.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after buying an additional 26,884 shares during the last quarter. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares in the last quarter. Franklin Resources Inc. boosted its stake in Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after acquiring an additional 139,647 shares in the last quarter. Capital World Investors boosted its stake in Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after acquiring an additional 32,348 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Royal Bank Of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research note on Monday. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research note on Monday. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Finally, TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron said its Lynozyfic (linvoseltamab) Phase 1/2 LINKER-AL2 trial in systemic AL amyloidosis produced rapid and deep responses, including free light chain normalization by day 15 and a 100% hematologic complete response rate at the highest dose, with signs of organ-function improvement. Article Title
• Neutral Sentiment: The Lynozyfic data could strengthen Regeneron’s hematology pipeline over time, but the treatment is still investigational for AL amyloidosis and the trial included safety issues such as infections, neutropenia and cytokine release syndrome. Article Title
• Neutral Sentiment: Regeneron also announced a milestone in its REGN7544 sepsis-induced hypotension study, adding another positive update from the pipeline, though the commercial impact is still uncertain. Article Title
• Negative Sentiment: Sentiment has been pressured by Regeneron’s recent disclosure that its Phase 3 melanoma trial for fianlimab plus Libtayo failed to meet its primary endpoint, raising concerns about the company’s near-term oncology prospects. Article Title
• Negative Sentiment: Multiple law firms have opened securities investigations tied to the melanoma trial miss, which can add overhang and keep traders cautious on REGN. Article Title

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $642.59 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a market capitalization of $67.93 billion, a price-to-earnings ratio of 15.66, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30. The firm has a 50-day simple moving average of $734.17 and a 200-day simple moving average of $745.67. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the firm earned $8.22 earnings per share. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.